While current
treatments for Alzheimer's Disease (AD) are only able to ease symptoms
temporarily, tau-based vaccines may offer a new and more effective way to treat
AD in the early course of the disease, says an analyst with research and
consulting firm GlobalData.
According to Kyle S.
Nicholson, PharmD, GlobalData's Analyst covering Neurology, tau-based therapies
for AD have traditionally been overlooked in favor of passive beta amyloid
immunotherapies, such as Eli Lilly's solanezumab and Roche's gantenerumab and
crenezumab.
Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob disease (CJD) is a rare form of degenerative brain disorder, or brain damage that leads to a rapid decrease of mental function and movement.
Advertisement
However, this interest appears to be receding after notable setbacks in recent years, and tau-based immunotherapies now have the potential to capture larger patient shares than these products.
Nicholson explains:
"Tau is one of two peptides linked to AD, and is known for forming tangles of
neuronal fibers inside the brain and causing cellular death. The other abnormal
protein believed to cause damage that leads to AD is beta amyloid."
![Diet and Alzheimer´s Disease]( "Diet and Alzheimer´s Disease")
Alzheimer''s begins with forgetfulness, but over time affects speech and coordination along with drastic behavioral changes. The right diet may lower your risk by 40%. So isn''t a diet change worth it?
"Doubts are starting to arise over whether or not the removal of beta amyloid will affect a patient's cognitive status. Given that tau-related pathology might occur before beta amyloid becomes implicated, a tau-based approach may have a greater chance of eliciting measurable effects earlier in the disease's progression."
The analyst notes that Johnson & Johnson and AC Immune have already entered into a three-year agreement to develop and commercialize tau-based immunotherapies for AD. These include ACI-35, which is currently in Phase IIb trials and positioned to be the first-in-class phosphorylated tau proteins vaccine inhibitor.
However, Nicholson adds: "Despite its potential first-in-class status, ACI-35 will encounter significant competition from disease-modifying passive immunotherapies and oral beta-secretase inhibitors, which will start populating the market in 2018."
"We expect AstraZeneca/Eli Lilly's AZD-3293 and Merck & Co.'s MK-8931 to capture over 15% of the global AD space by 2023. ACI-35 will therefore likely enter a highly competitive arena several years after the beta amyloid therapies have already taken a significant patient share," the analyst concludes.
Source: Medindia
Diet and Alzheimer´s Disease
Alzheimer''s begins with forgetfulness, but over time affects speech and coordination along with drastic behavioral changes. The right diet may lower your risk by 40%. So isn''t a diet change worth it?
Advertisement
"Doubts are starting to arise over whether or not the removal of beta amyloid will affect a patient's cognitive status. Given that tau-related pathology might occur before beta amyloid becomes implicated, a tau-based approach may have a greater chance of eliciting measurable effects earlier in the disease's progression."
The analyst notes that Johnson & Johnson and AC Immune have already entered into a three-year agreement to develop and commercialize tau-based immunotherapies for AD. These include ACI-35, which is currently in Phase IIb trials and positioned to be the first-in-class phosphorylated tau proteins vaccine inhibitor.
However, Nicholson adds: "Despite its potential first-in-class status, ACI-35 will encounter significant competition from disease-modifying passive immunotherapies and oral beta-secretase inhibitors, which will start populating the market in 2018."
"We expect AstraZeneca/Eli Lilly's AZD-3293 and Merck & Co.'s MK-8931 to capture over 15% of the global AD space by 2023. ACI-35 will therefore likely enter a highly competitive arena several years after the beta amyloid therapies have already taken a significant patient share," the analyst concludes.
Source: Medindia
Therapies That Reduce Apolipoprotein E may Have the Potential to Treat Alzheimer’s Disease
Researchers suggest that therapies that can reduce the levels of apolipoprotein E (apoE) could have the potential to treat neurodegenerative disorders such as Alzheimer disease.
Advertisement
 Anti-Aging Protein can Slowdown or Prevent Alzheimer’s DiseaseUsing anti-aging protein Klotho in pretreatment of neurons can prevent neuron death in the presence of the toxic amyloid protein and glutamate. | Advertisement
|
Advertisement
Recommended Reading
Latest Mental Health News
Americans exhibit high intelligence in one IQ category despite lower scores in others according to a new study.
New study confirms a drop in suicide rates across 15 European countries, while Turkey sees a significant increase.
Lesbian, gay, and bisexual youth experience sleep problems due to depression, stress, and family conflict.
Are mental health services important for tuberculosis treatment? Integrating mental health services into the Tuberculosis program can improve treatment completion.
Sleep interventions such as melatonin treatment could be considered to reduce the risk of self-harm in young females with depression and anxiety, instead of medications.